查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1133474

全球术后疼痛治疗市场 - 2022-2029

Global Post-operative Pain Therapeutics Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 250 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

术后疼痛治疗药物市场的增长是由手术数量的增加、市场上新药的推出和研发活动、新兴国家老年人口的增加、患病率的增加所推动的急性疾病的增加，以及参与手术和手术的患者数量的增加。

手术数量的增加有望推动市场增长

癌症和眼科等各种手术数量的增加预计将在预测期内提振市场。根据美国整形外科医师协会 2020 年数据报告，2020 年将进行约 1560 万例整容手术，其中 230 万例为整容手术，1320 万例为微创整容手术。此外，女性接受整容手术的次数比男性多，2020年，女性约占所有整容手术的92%，男性约占所有整容手术的8%。此外，在 13-19 岁的儿童中，只有 2% 的儿童参与了手术。常见的青少年手术包括眼睑手术、鼻整形术、耳部手术、激光脱毛和激光换肤。一位医疗保健提供者推荐使用非甾体抗炎药来帮助减轻整容手术后的疼痛。

此外，根据发表在《南非生理学杂誌》上的一篇论文，骨关节炎在 40 岁时的发病/进展率估计为 22%。如果疾病更严重且有限的管理不能有效缓解疼痛，医疗专业人员建议进行关节置换手术。随着手术数量的增加，全球对术后药物的需求也在增加。

术后疼痛治疗药物的副作用阻碍市场增长

但是，所有药物都有副作用，例如，所有阿片类药物都有限制其使用的副作用。与阿片类药物使用相关的主要副作用是呼吸抑制。与药物过量和术后止痛药相关的副作用案例不断增加，限制了整个市场的增长。

COVID-19 影响分析

COVID-19 的出现对全球术后止痛药市场产生了重大影响。 2020 年 3 月，美国总统宣布进入全国卫生紧急状态，导致全国范围内的非必要活动暂停。包括美国外科医师学会 (ACS) 在内的主要外科学会在 3 月中旬宣布，尽量减少、推迟或取消择期手术，并发布了按外科专业进行择期手术分诊的指南。医疗保险和医疗补助服务中心 (CMS) 和美国外科医生也发表声明，建议推迟不必要的手术。 2022 年 2 月，发表在《外科前沿》上的一篇论文发现，在大流行期间推迟择期手术导致外科诊所的手术减少。手术量的下降表明大流行后外科诊所和医院的工作量严重增加。

此外，大流行的担忧正在推迟对常见肿瘤，尤其是乳腺癌的诊断，从而导致肿瘤进一步进展和疾病进展。此外，在第一波大流行期间，乳腺癌手术数量，尤其是首次手术数量减少了约 50-60%。随着我们从大流行中恢復过来，越来越多的医院定期为患者提供足够的护理，甚至为患者进行手术，从而推动了全球术后疼痛市场。

您可以在全球术后疼痛治疗市场报告中访问大约 70 多个市场数据表、65 多个图表和 250 多个页面（大约）。

内容

第一章市场研究方法和范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

  • 按药物类型：市场细分
  • 按管理途径：市场细分
  • 按疼痛类型：市场细分
  • 按分销渠道：市场细分
  • 按地区：市场细分

第 4 章市场动态

  • 市场影响因素
    • 驱动程序
      • 手术次数增加
      • 新药上市数量增加
    • 限制
    • 与术后止痛药相关的副作用
    • 影响分析

第五章行业分析

  • 波特五力分析
  • 供应链分析
  • 监管分析
  • 定价分析
  • 未满足的需求分析

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按药物类型

  • 阿片类药物
  • 非甾体抗炎药
  • 糖皮质激素
  • 局部麻醉剂
  • 三环类抗抑郁药
  • 抗癫痫药
  • 其他

第 8 章给药途径

  • 口语
  • 静脉给药
  • 肌肉注射
  • 其他

第 9 章按疼痛类型

  • 神经性疼痛
  • 伤害性疼痛

第 10 章按销售渠道

  • 医院药房
  • 零售药房
  • 在线药店
  • 电子商务
  • 其他

第 11 章按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 12 章竞争格局

  • 主要发展和战略
  • 公司份额分析
  • 按治疗类型划分的基准

第 13 章公司简介

  • Mallinckrodt 製药公司
    • 公司概况
    • 治疗类型组合和描述
    • 主要亮点
    • 财务摘要
  • Trevena Inc.
  • Heron Therapeutics
  • Teva Pharmaceutical Industries Ltd.
  • Camarus
  • Bayer AG
  • Pacira BioSciences Inc.
  • Pfizer Inc.
  • Novartis AG
  • Hyloris Pharmaceuticals SA
  • Eli Lilly & Company

第 14 章全球术后止痛药市场-DataM

简介目录
Product Code: DMPH5858

Market Overview

Post-Operative Pain Therapeutics Market size was valued at US$ xx million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of x% during the forecast period (2022-2029).

Postsurgical or postoperative pain is long-lasting after surgery; it is nearly 3 to 6 months. The pain varies from patient to patient as well as quality and location from the pain experienced before the surgery, and it is usually related to iatrogenic neuropathic pain caused by surgical injury to a crucial peripheral nerve. While most all surgeries can lead to postoperative pain, some surgeries have a high risk of causing nerve damage, such as breast and thoracic surgery, leg amputation, inguinal hernia repair, and coronary artery bypass surgery. To reduce this pain, various medications are used, such as NSAIDs.

Market Dynamics

The post-operative pain therapeutics market growth is driven by the rise in the number of surgeries, launching of new drugs in the market and research and development activities, rising geriatric population in developing countries, growing prevalence of acute diseases, and increasing patient awareness related to surgeries and operations.

The rising number of surgeries is expected to drive the market growth

The rising number of different surgeries, such as cancer and eye, is expected to boost the market over the forecast period. As per the American Society of Plastic Surgeons 2020 data report, nearly 15.6 million cosmetic procedures were performed in 2020, of which 2.3 million were cosmetic surgical procedures and 13.2 million cosmetic minimally-invasive procedures. Furthermore, females have a higher number of cosmetic surgeries than males, with females performing approximately 92% of all cosmetic procedures and males performing approximately 8% of all cosmetic procedures in 2020. Furthermore, among the children who are in the 13-19 age group, only 2% of the total contributed to the surgeries. Some of the most common procedures for teens include eyelid surgery, nose reshaping, ear surgery, laser hair removal, and laser skin resurfacing. The healthcare professional recommended the NSAID drugs to reduce the pain of this after cosmetic surgery.

Moreover, according to the article published in the South African Journal of Physiology, osteoarthritis has an occurrence and progression rate of 22% at 40 years of age. At the more advanced stage of disease progression and when limited management fails to provide the individual with effective pain relief, then joint replacement surgery is recommended by the health care professional. The increase in surgeries simultaneously increases the demand for post-operative therapeutics worldwide.

The side effects of post-operative pain therapeutics will hamper the growth of the market

However, all drugs have side effects, for instance, all opioids have their side effects which is limiting their use. The major side effect related to the use of opioids is respiratory depression. The rising cases of a drug overdose and side effects associated with postoperative pain drugs are limits to the overall market growth.

COVID-19 Impact Analysis

The appearance of COVID-19 considerably impacted the global post-operative pain therapeutics market. In March 2020, the United States president announced a national health emergency that resulted in a shutdown of all less necessary activities throughout the country. The American College of Surgeons (ACS) and other major surgical specialty societies declared that they would be minimizing, postponing, or canceling elective surgical procedures in mid-March and published guidelines for triage of elective surgical procedures by surgical specialty. The Centers for Medicare & Medicaid Services (CMS) and the US Surgeon General also published statements and gave suggestions for the postponement of unnecessary surgical procedures. In addition, in February 2022, as per the article published in Frontiers in Surgery the number of operations in surgical clinics was reduced because of the postponement of selective operations during the pandemic period. The drop in the number of surgeries indicates a serious rise in the workload on surgical clinics and hospitals in the post-pandemic period.

Furthermore, due to pandemic concerns, delays in diagnosis, especially in tumors of typical interest such as breast cancer, result in further advanced-stage tumors and disease progression. Moreover, the number of surgeries for breast cancer, especially upfront surgeries, dropped by around 50-60% in the first wave of the pandemic period. As the situation is recovering from the pandemic, more hospitals are regularly giving the proper treatment and they are performing surgeries on the patients, which is boosting the postoperative pain market worldwide.

Segment Analysis

The NSAIDs segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The NSAIDs segment is expected to boost the market over the period of the forecast. NSAIDs are a broad-ranging class of drugs with multiple characteristics such as cyclo-oxygenase (COX)-1 or COX-2 selectivity, targeted action, and analgesic potency. In March 2022, as per the article published in Pharmacological Management of Postoperative Pain, the clinical guidelines to manage postoperative pain were issued by the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' Committee on Regional Anesthesia, outlined a strong suggestion based on high-quality evidence that physicians or clinicians provide adult and paediatric patients with paracetamol or acetaminophen (APAP) or nonsteroidal anti-inflammatory drugs (NSAIDs) as part of a multimodal analgesic regimen to handle the postoperative pain unless there are any specific contraindications. NSAIDs can have potent central effects similar to those of opioids. In addition, the quick onset of analgesic activity is a key prescribing consideration for treating acute postoperative pain. For instance, the study analysing and validating the rate of onset of a variety of NSAIDs in dental pain found that dexketoprofen 25 mg was so much faster (30 minutes) than diclofenac 50 mg (60 minutes), tramadol 100 mg (120 minutes), and piroxicam 20 mg (120 minutes). Because of its rapid onset of action, there is an increasing demand for NSAIDs in the market to treat postoperative pain.

Geographical Analysis

North America region holds the largest market share of the global post-operative pain therapeutics market

North America dominates the market for post-operative pain therapeutics and is expected to show a similar trend over the forecast period. It is estimated to hold a significant market size over the forecast period (2022-2029) owing to increasing number of surgeries, advanced healthcare systems, easily availability of therapeutics for treatment. The launching new drugs development, research activity and approval of various drugs drive the market in the North American region. For instance, in March 2022, Virpax Pharmaceuticals, Inc. is completed all FDA-required pre-clinical studies for Epoladerm Virpax's investigational pre-filled topical spray analgesic product to manage chronic pain associated with osteoarthritis (OA) of the knee. The key Investigational New Drug Application (IND) allows studies to be completed, on irritation, dermal toxicity phototoxicity and pharmacokinetic characteristics.

Furthermore, in June 2022, Heron Therapeutics, Inc. announced the online publication of a new study evaluating the efficacy and safety of ZYNRELEF (bupivacaine and meloxicam) extended-release solution as the foundation of a perioperative non-opioid multimodal analgesic (MMA) regimen in patients undergoing total knee arthroplasty (TKA). The ZYNRELEF is approved by the U.S. Food and Drug Administration (FDA) for use in adults for soft tissue or peri-articular instillation to produce postsurgical analgesia for up to 72 hours after foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures.

Competitive Landscape

The Post-operative Pain Therapeutics market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market are Mallinckrodt Pharmaceuticals, Trevena Inc., Heron Therapeutics, Teva Pharmaceutical Industries Ltd., Camarus, Bayer AG, Pacira BioSciences Inc., Pfizer Inc., Novartis AG, Hyloris Pharmaceuticals SA, and Eli Lilly & Company among others. The major players are adopting several growth strategies such as Treatment type launches, acquisitions, and collaborations, which are contributing to the growth of the post-operative pain therapeutics market globally.

For instance,

  • In November 2021, Antibe Therapeutics Inc. is pleased to provide additional detail on otenaproxesul's development plan for acute pain indications. Further, this drugs can used for post-operative pain, as a safe non-opioid analgesic.

Hyloris Pharmaceuticals SA

Overview:

Hyloris is a biopharma company involved in innovating, reinventing, and optimizing existing medications to direct important healthcare necessities and deliver related improvements for patients, healthcare professionals and payors. Hyloris has a patented portfolio of 13 repurposed and reformulated modernized medicines that have the potential to provide remarkable advantages over other alternatives.

Treatment type Portfolio:

Maxigesic IV: Maxigesic IV is a novel, patented; non-opioid used for treatment of post-operative pain and is a distinctive combination of 1000 mg paracetamol and 300 mg ibuprofen solution for infusion. It is currently licensed in more than 100 countries across the world, and registered in 24 countries. It is now available in 5 countries including Australia, New Zealand, The United Arab Emirates, Germany, and Austria.

The global post-operative pain therapeutics market report would provide access to approximately 70+ market data tables, 65+ figures, and in the range of 250+ (approximate) pages.

Table of Contents

1. Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet By Drug Type
  • 3.2. Market snippet By Route of Administration
  • 3.3. Market snippet By Type of Pain
  • 3.4. Market snippet By Distribution Channel
  • 3.5. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The rising Number of Surgeries
      • 4.1.1.2. The increasing launching of new drugs
    • 4.1.2. Restraints:
    • 4.1.3. The side effects related to post-operative pain therapeutics
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis
  • 5.4. Pricing Analysis
  • 5.5. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Drug Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type Segment
    • 7.1.2. Market Attractiveness Index, By Drug Type Segment
  • 7.2. Opioids*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. NSAIDs
  • 7.4. Glucocorticoids
  • 7.5. Local Anesthetics
  • 7.6. Tricyclic Antidepressants
  • 7.7. Antiepileptic drugs
  • 7.8. Others

8. By Route of Administration

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.1.2. Market Attractiveness Index, By Route of Administration
  • 8.2. Oral*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Intravenous
  • 8.4. Intramuscular
  • 8.5. Others

9. By Type of Pain

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Pain Market Attractiveness Index, By Type of Pain
  • 9.2. Neuropathic Pain*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Nociceptive Pain

10. By Distribution Channel

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.1.2. Market Attractiveness Index, By Distribution Channel
  • 10.2. Hospital Pharmacies*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Retail Pharmacies
  • 10.4. Online Pharmacies
  • 10.5. E-commerce
  • 10.6. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Pain
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. The U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Pain
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Pain
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Pain
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type of Pain
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Treatment type Benchmarking

13. Company Profiles

  • 13.1. Mallinckrodt Pharmaceuticals*
    • 13.1.1. Company Overview
    • 13.1.2. Treatment type Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Trevena Inc.
  • 13.3. Heron Therapeutics
  • 13.4. Teva Pharmaceutical Industries Ltd.
  • 13.5. Camarus
  • 13.6. Bayer AG
  • 13.7. Pacira BioSciences Inc.
  • 13.8. Pfizer Inc.
  • 13.9. Novartis AG
  • 13.10. Hyloris Pharmaceuticals SA
  • 13.11. Eli Lilly & Company

LIST NOT EXHAUSTIVE

14. Global Post-operative Pain Therapeutics Market- DataM

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us